ucb7858
mAbexperimental
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jul 1, 2016 (NCT02879877)
Timeline
2010s
- Jan 1, 2016
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
TGM2 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4650430 ↗
Also known as
- ucb7858
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04705350 | Phase 1 | Jan 11, 2021 | UCB |
| NCT04335578 | Phase 1/Phase 2 (Phase 2) | Oct 21, 2019 | UCB |
| NCT02879877 | Phase 1 | Jul 1, 2016 | Hoosier Cancer Research Network, Parexel |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| UCB | For profit | 2 | 2 | 2 | 2019 |
| Hoosier Cancer Research Network | Academic/Hospital | 1 | 1 | 1 | 2016 |
| Parexel | For profit | 1 | 0 | 1 | 2016 |
3 organizations
Page 1 / 1